These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 9854192

  • 1. Arguments for the long-term use of combined androgen blockade.
    Wajsman Z.
    Eur Urol; 1998; 34 Suppl 3():25-8. PubMed ID: 9854192
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Arguments against the long-term use of combined androgen blockade.
    Studer UE, Mills RD.
    Eur Urol; 1998; 34 Suppl 3():29-32. PubMed ID: 9854193
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combined androgen blockade.
    Crawford ED.
    Eur Urol; 1996; 29 Suppl 2():54-61. PubMed ID: 8717465
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group.
    Bono AV, DiSilverio F, Robustelli della Cuna G, Benvenuti C, Brausi M, Ferrari P, Gibba A, Galli L.
    Urol Int; 1998; 60 Suppl 1():18-24. PubMed ID: 9563140
    [Abstract] [Full Text] [Related]

  • 11. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
    Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJ.
    Urology; 2000 Mar; 55(3):391-5; discussion 395-6. PubMed ID: 10699617
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
    Figg WD, Kroog G, Duray P, Walther MM, Patronas N, Sartor O, Reed E.
    Cancer; 1997 May 15; 79(10):1964-8. PubMed ID: 9149024
    [Abstract] [Full Text] [Related]

  • 17. Hormonal therapy of prostate cancer.
    Labrie F.
    Prog Brain Res; 2010 May 15; 182():321-41. PubMed ID: 20541672
    [Abstract] [Full Text] [Related]

  • 18. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P, Castagnetti G, Ferrari G, Baisi B, Dotti A.
    Urol Int; 1996 May 15; 56 Suppl 1():13-7. PubMed ID: 8776812
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
    Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.
    J Urol; 2018 Nov 15; 200(5):956-966. PubMed ID: 29730201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.